Waters Corporation and Labcorp Announce Partnership for HPV Screening
Waters Corporation and Labcorp have entered into a partnership to provide the FDA-approved BD Onclarity HPV Assay across Labcorp's U.S. laboratory network.
Stocks · News reference
Guggenheim Maintains Buy on Waters, Raises Price Target to $490
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Live On CNBC, Josh Brown Hosts Segment Titled "Josh's Best Stocks In The Market: Waters"
Barclays Maintains Overweight on Waters, Raises Price Target to $500
Barclays analyst Luke Sergott maintains Waters (NYSE:WAT) with a Overweight and raises the price target from $460 to $500.
Nvidia, Micron and Other 5 S&P 500 Stocks With +100% Revenue Growth
Micron, Sandisk and Nvidia lead seven S&P 500 stocks that more than doubled quarterly revenue. Six sell AI hardware.